Sara M. Tolaney on Neoadjuvant Treatment Considerations for Triple-Negative Breast Cancer

Sara M. Tolaney

There are many clinical trial opportunities, Tolaney says, before surgery.

Sara M. Tolaney, medical oncologist, Dana-Farber Cancer Institute, discusses neoadjuvant treatment considerations for patients with triple-negative breast cancer.

“[There are] lots of potential clinical trial opportunities prior to surgery because we do have this question about whether or not platinum therapy is beneficial,” Tolaney says.